Depakote® ER (Divalproex Sodium) Extended-Release Tablet

Depakote® ER is an extended-release formulation of divalproex sodium, a medication prescribed to manage various neurological and psychiatric conditions. This pharmaceutical product delivers consistent therapeutic levels throughout the day, reducing the need for multiple daily doses while maintaining stable drug concentrations in the bloodstream.

Divalproex sodium functions as a combination of valproic acid and sodium valproate, working through multiple mechanisms to stabilize neural activity and regulate neurotransmitter function. The extended-release mechanism allows for once-daily or twice-daily dosing schedules, improving medication adherence and patient convenience compared to immediate-release alternatives.

Depakote® ER is commonly prescribed for bipolar disorder management, particularly for acute manic episodes and maintenance therapy to prevent mood destabilization. Healthcare providers also utilize this medication for epilepsy and seizure disorder control across various seizure types, as well as for migraine prophylaxis in patients experiencing frequent migraine headaches.

The extended-release formulation is designed to minimize gastrointestinal side effects associated with immediate-release formulations, offering improved tolerability for long-term treatment. Each tablet contains precisely measured divalproex sodium, ensuring consistent dosing and therapeutic efficacy with every administration.

This medication requires careful monitoring and should only be used under direct medical supervision and prescription. Individual dosing must be determined by a qualified healthcare provider based on the patient's specific condition, medical history, concurrent medications, and treatment response. Regular laboratory monitoring may be necessary to ensure therapeutic levels and monitor for potential adverse effects during extended treatment periods.